Effects of alirocumab on triglyceride metabolism: a fat-tolerance test and nuclear magnetic resonance spectroscopy study

Background: PCSK9 antibodies strongly reduce LDL cholesterol. The effects of PCSK9 antibodies on triglyceride metabolism are less pronounced. The present study aimed to investigate in detail the effects of alirocumab on triglycerides, triglyceride-rich lipoproteins, and lipase regulators. Methods: A...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Metzner, Thomas (VerfasserIn) , Leitner, Deborah R. (VerfasserIn) , Mellitzer, Karin (VerfasserIn) , Beck, Andrea (VerfasserIn) , Sourij, Harald (VerfasserIn) , Stojakovic, Tatjana (VerfasserIn) , Reishofer, Gernot (VerfasserIn) , März, Winfried (VerfasserIn) , Landmesser, Ulf (VerfasserIn) , Scharnagl, Hubert (VerfasserIn) , Toplak, Hermann (VerfasserIn) , Silbernagel, Günther (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 17 January 2022
In: Biomedicines
Year: 2022, Jahrgang: 10, Heft: 1, Pages: 1-13
ISSN:2227-9059
DOI:10.3390/biomedicines10010193
Online-Zugang:Verlag, kostenfrei, Volltext: https://doi.org/10.3390/biomedicines10010193
Verlag, kostenfrei, Volltext: https://www.mdpi.com/2227-9059/10/1/193
Volltext
Verfasserangaben:Thomas Metzner, Deborah R. Leitner, Karin Mellitzer, Andrea Beck, Harald Sourij, Tatjana Stojakovic, Gernot Reishofer, Winfried März, Ulf Landmesser, Hubert Scharnagl, Hermann Toplak and Günther Silbernagel

MARC

LEADER 00000caa a2200000 c 4500
001 1845499387
003 DE-627
005 20230706223740.0
007 cr uuu---uuuuu
008 230516s2022 xx |||||o 00| ||eng c
024 7 |a 10.3390/biomedicines10010193  |2 doi 
035 |a (DE-627)1845499387 
035 |a (DE-599)KXP1845499387 
035 |a (OCoLC)1389533130 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Metzner, Thomas  |e VerfasserIn  |0 (DE-588)1289100519  |0 (DE-627)1845241029  |4 aut 
245 1 0 |a Effects of alirocumab on triglyceride metabolism  |b a fat-tolerance test and nuclear magnetic resonance spectroscopy study  |c Thomas Metzner, Deborah R. Leitner, Karin Mellitzer, Andrea Beck, Harald Sourij, Tatjana Stojakovic, Gernot Reishofer, Winfried März, Ulf Landmesser, Hubert Scharnagl, Hermann Toplak and Günther Silbernagel 
264 1 |c 17 January 2022 
300 |a 13 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 16.05.2023 
520 |a Background: PCSK9 antibodies strongly reduce LDL cholesterol. The effects of PCSK9 antibodies on triglyceride metabolism are less pronounced. The present study aimed to investigate in detail the effects of alirocumab on triglycerides, triglyceride-rich lipoproteins, and lipase regulators. Methods: A total of 24 patients with an indication for treatment with PCSK9 antibodies were recruited. There were two visits at the study site: the first before initiation of treatment with alirocumab and the second after 10 weeks of treatment. Fat-tolerance tests, nuclear magnetic resonance spectroscopy, and enzyme-linked immunosorbent assays were performed to analyze lipid metabolism. Results: A total of 21 participants underwent the first and second investigation. Among these, two participants only received alirocumab twice and 19 patients completed the trial per protocol. All of them had atherosclerotic vascular disease. There was no significant effect of alirocumab treatment on fasting triglycerides, post-prandial triglycerides, or lipoprotein-lipase regulating proteins. Total, large, and small LDL particle concentrations decreased, while the HDL particle concentration increased (all p < 0.001). Mean total circulating PCSK9 markedly increased in response to alirocumab treatment (p < 0.001). Whereas PCSK9 increased more than three-fold in all 19 compliant patients, it remained unchanged in those two patients with two injections only. Conclusion: Significant effects of alirocumab on triglyceride metabolism were not detectable in the ALIROCKS trial. The total circulating PCSK9 concentration might be a useful biomarker to differentiate non-adherence from non-response to PCSK9 antibodies. 
650 4 |a alirocumab 
650 4 |a fat-tolerance test 
650 4 |a lipids 
650 4 |a nuclear magnetic resonance spectroscopy 
650 4 |a PCSK9 
700 1 |a Leitner, Deborah R.  |e VerfasserIn  |4 aut 
700 1 |a Mellitzer, Karin  |e VerfasserIn  |4 aut 
700 1 |a Beck, Andrea  |e VerfasserIn  |4 aut 
700 1 |a Sourij, Harald  |e VerfasserIn  |4 aut 
700 1 |a Stojakovic, Tatjana  |e VerfasserIn  |0 (DE-588)1254244131  |0 (DE-627)1796841706  |4 aut 
700 1 |a Reishofer, Gernot  |e VerfasserIn  |4 aut 
700 1 |a März, Winfried  |d 1958-  |e VerfasserIn  |0 (DE-588)1027603599  |0 (DE-627)729463605  |0 (DE-576)373454635  |4 aut 
700 1 |a Landmesser, Ulf  |e VerfasserIn  |4 aut 
700 1 |a Scharnagl, Hubert  |e VerfasserIn  |0 (DE-588)1100175954  |0 (DE-627)859149919  |0 (DE-576)18647525X  |4 aut 
700 1 |a Toplak, Hermann  |e VerfasserIn  |0 (DE-588)1121248624  |0 (DE-627)874197910  |0 (DE-576)480789487  |4 aut 
700 1 |a Silbernagel, Günther  |e VerfasserIn  |0 (DE-588)1069585556  |0 (DE-627)822063751  |0 (DE-576)42929235X  |4 aut 
773 0 8 |i Enthalten in  |t Biomedicines  |d Basel : MDPI, 2013  |g 10(2022), 1, Artikel-ID 193, Seite 1-13  |h Online-Ressource  |w (DE-627)750370483  |w (DE-600)2720867-9  |w (DE-576)384589596  |x 2227-9059  |7 nnas  |a Effects of alirocumab on triglyceride metabolism a fat-tolerance test and nuclear magnetic resonance spectroscopy study 
773 1 8 |g volume:10  |g year:2022  |g number:1  |g elocationid:193  |g pages:1-13  |g extent:13  |a Effects of alirocumab on triglyceride metabolism a fat-tolerance test and nuclear magnetic resonance spectroscopy study 
856 4 0 |u https://doi.org/10.3390/biomedicines10010193  |x Verlag  |x Resolving-System  |z kostenfrei  |3 Volltext 
856 4 0 |u https://www.mdpi.com/2227-9059/10/1/193  |x Verlag  |z kostenfrei  |3 Volltext 
951 |a AR 
992 |a 20230516 
993 |a Article 
994 |a 2022 
998 |g 1027603599  |a März, Winfried  |m 1027603599:März, Winfried  |d 60000  |d 61400  |e 60000PM1027603599  |e 61400PM1027603599  |k 0/60000/  |k 1/60000/61400/  |p 8 
999 |a KXP-PPN1845499387  |e 4322732100 
BIB |a Y 
SER |a journal 
JSO |a {"note":["Gesehen am 16.05.2023"],"name":{"displayForm":["Thomas Metzner, Deborah R. Leitner, Karin Mellitzer, Andrea Beck, Harald Sourij, Tatjana Stojakovic, Gernot Reishofer, Winfried März, Ulf Landmesser, Hubert Scharnagl, Hermann Toplak and Günther Silbernagel"]},"recId":"1845499387","origin":[{"dateIssuedDisp":"17 January 2022","dateIssuedKey":"2022"}],"person":[{"role":"aut","display":"Metzner, Thomas","given":"Thomas","family":"Metzner"},{"display":"Leitner, Deborah R.","role":"aut","family":"Leitner","given":"Deborah R."},{"display":"Mellitzer, Karin","role":"aut","family":"Mellitzer","given":"Karin"},{"role":"aut","display":"Beck, Andrea","given":"Andrea","family":"Beck"},{"role":"aut","display":"Sourij, Harald","given":"Harald","family":"Sourij"},{"given":"Tatjana","family":"Stojakovic","role":"aut","display":"Stojakovic, Tatjana"},{"display":"Reishofer, Gernot","role":"aut","family":"Reishofer","given":"Gernot"},{"family":"März","given":"Winfried","display":"März, Winfried","role":"aut"},{"display":"Landmesser, Ulf","role":"aut","family":"Landmesser","given":"Ulf"},{"given":"Hubert","family":"Scharnagl","role":"aut","display":"Scharnagl, Hubert"},{"given":"Hermann","family":"Toplak","role":"aut","display":"Toplak, Hermann"},{"given":"Günther","family":"Silbernagel","role":"aut","display":"Silbernagel, Günther"}],"language":["eng"],"relHost":[{"disp":"Effects of alirocumab on triglyceride metabolism a fat-tolerance test and nuclear magnetic resonance spectroscopy studyBiomedicines","note":["Gesehen am 12.08.20"],"physDesc":[{"extent":"Online-Ressource"}],"title":[{"subtitle":"open access journal","title":"Biomedicines","title_sort":"Biomedicines"}],"language":["eng"],"origin":[{"publisherPlace":"Basel","dateIssuedKey":"2013","publisher":"MDPI","dateIssuedDisp":"2013-"}],"recId":"750370483","type":{"bibl":"periodical","media":"Online-Ressource"},"id":{"zdb":["2720867-9"],"issn":["2227-9059"],"eki":["750370483"]},"part":{"pages":"1-13","issue":"1","text":"10(2022), 1, Artikel-ID 193, Seite 1-13","volume":"10","extent":"13","year":"2022"},"pubHistory":["1.2013 -"]}],"title":[{"title_sort":"Effects of alirocumab on triglyceride metabolism","subtitle":"a fat-tolerance test and nuclear magnetic resonance spectroscopy study","title":"Effects of alirocumab on triglyceride metabolism"}],"id":{"doi":["10.3390/biomedicines10010193"],"eki":["1845499387"]},"type":{"bibl":"article-journal","media":"Online-Ressource"},"physDesc":[{"extent":"13 S."}]} 
SRT |a METZNERTHOEFFECTSOFA1720